Patient case: 32-year-old male with dilated cardiomyopathy; genetic feature: LMNA

Clinical trial: Pulse Reduction On Beta-blocker and Ivabradine Therapy

Summary: Heart failure with reduced left ventricular ejection fraction (HFrEF) is the most common form of chronic heart failure in subjects ≤ 75 years of age. Beta-blocker therapy greatly reduces mortality and improves ventricular function in HFrEF patients, but 30-40% of patients do not show improvement in ventricular function with beta blockade.
  An extensive gene signaling network downstream from the beta1-adrenergic receptor, the primary target of beta-blocker therapy is likely important for development and progression HFrEF. Pathologic changes in this gene signaling network are only reversed towards normal levels when ventricular function improves. One potential mechanism for failure to improve ventricular function in HFrEF patients unresponsive to beta blocker therapy is a lack of heart rate reduction.
  Ivabradine is an FDA-approved medication believed to have therapeutic benefit in HFrEF patients through reduction in heart rate independent of beta-blockade. Ivabradine has been shown to reduce the risk of hospitalization for worsening HF in patients with stable, symptomatic chronic heart failure with reduced EF (≤ 35%)in sinus rhythm with resting heart rate ≥ 70 bpm and who are on maximally tolerated doses of beta blockers or who have a contraindication to beta blockers.
  Given the high rate of mortality and hospitalization of HFrEF patients even with current therapies, there is a large unmet need for improving HFrEF therapy. The goals of this study are to test the hypothesis that heart rate reduction is an important antecedent for improvement in ventricular function, and to identify components of the beta1-adrenergic receptor gene signaling network responsible for improvement in ventricular function caused by heart rate reduction.

Detailed description: The Pulse Reduction on Beta-blocker and Ivabradine Therapy (PROBE-IT) Study is a double-blind, randomized, two-arm parallel group, placebo-controlled design that compares the effect of heart rate reduction on ventricular reverse remodeling (assessed by LVEF change at 24 weeks) and on the beta1-gene signaling network in NYHA Class I-III HFrEF patients with an idiopathic dilated cardiomyopathy etiology (HFrEF/IDC), who are in sinus rhythm and whose heart rates remain ≥ 70 bpm on target or maximally tolerated doses of beta-blockers to which they have evidence of non-response by LVEF (< 5 absolute percentage points).
  Eligible patients will be randomized (2:1) to blinded treatment with ivabradine or matching placebo and will be initiated as per Corlanor® prescribing information over 4 weeks. The dose at 4 weeks post randomization will be considered the intention-to-treat end of titration dose, but further dose adjustment can be made based on clinical factors.
  The primary endpoint, i.e., effect of heart rate reduction on reverse remodeling (LVEF), will be assessed after 24 weeks. LV phenotyping by 3D-echocardiography, endomyocardial biopsy and coronary sinus sampling for cardiac norepinephrine levels will be performed at baseline and at 24 weeks. Exercise testing at baseline will be performed to assess level of beta blockade. Upon completion of the study, gene expression in endomyocardial biopsy tissue samples for each patient will be quantified using RNA-seq and quantified with respect to phenotypic measurements including LVEF and heart rate changes.
  After the Week 24 Visit, patients will return for an End-of-Study Visit and be offered open label ivabradine with dose initiation accomplished by stopping study drug and starting Corlanor at 5 mg BID or 2.5 mg BID if the patient is taking that dose of study drug. Investigators and patients will not be informed of the blinded study drug assignment at the time of study completion.

Eligibility: Inclusion Criteria:
  1. Age ≥ 18 years.
  2. History of non-ischemic (confirmed by coronary angiogram), non-valvular dilated cardiomyopathy considered to be idiopathic, HFrEF NYHA Class I, II, or III.
  3. Must have experienced a sign or symptom of clinical heart failure at some time within the preceding 12 months.
  4. In sinus rhythm at Screening Visit.
  5. Resting HR ≥ 70 bpm at the Screening Visit.
  6. Receiving guideline-indicated oral renin-angiotensin-adosterone system (RAAS) inhibitor therapy at the Randomization Visit, i.e., an ACE inhibitor, angiotensin receptor blocker, or sacubitril/valsartan plus a mineralocorticoid receptor antagonist as tolerated.
  7. May have ICD or CRT device as indicated.
  8. Receiving beta-blocker therapy for ≥ 6 months and target doses for ≥ 3 months prior to Baseline Visit.
  Target dose of carvedilol is 25 mg BID, and metoprolol succinate, 150 mg/day. Patients who are not receiving doses that are at least at these target levels will have their heart failure beta-blocker up-titrated to target and an LVEF re-measured in 3 months, at which time they could be eligible for enrollment. Patients on < target doses who are intolerant to higher than target doses may be enrolled.
  9. Evidence of stable or declining LVEF, defined as no increase by ≥ 5 % on a measurement done within 6 months of screening compared to the most recent historical measurement performed within 36 months of the index measure. Must have been on a dose of ≥ 50% of target during the period that documented the lack of a reverse remodeling response. Prior LVEF measurements could have been performed by any imaging technique, e.g., echocardiography, radionuclide methods, MRI, or contrast ventriculography.
  10. Women of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline and Randomization Visits.
  a. Women who are surgically sterile or post-menopausal for at least 12 months are not considered to be of childbearing potential.
  11. Women of childbearing potential must agree to use a highly effective contraception for the duration of the trial and for at least 30 days following the last dose of study drug.
  12. Must be competent to understand the information given in the Institutional Review Board (IRB) informed consent form (ICF).
  13. Echocardiographic parasternal window adequate for measuring LV volumes by 3D-echo.
  14. Must sign the ICF prior to the initiation of any study procedure and not withdraw consent prior to the Randomization Visit.
  Exclusion Criteria:
  1. NYHA Class IV symptoms at the Randomization Visit.
  2. History of HF due to or associated with uncorrected primary valvular disease or history of ischemic heart disease.
  3. Any history of atrial fibrillation (even if in sinus rhythm at present).
  4. Systolic blood pressure < 90/50 mmHg at the Screening Visit.
  5. Significant fluid overload at the Randomization Visit, in the opinion of the Investigator.
  Evidence of significant fluid overload may include:
  1. Mean jugular venous pressure above the clavicle at 90°.
  2. Liver congestion.
  3. Moist pulmonary rales post-cough.
  4. Peripheral edema beyond 1+ pedal not explained by local factors.
  6. History of untreated symptomatic bradycardia or if symptomatic bradycardia is likely on full dose of study drug in the opinion of the Investigator.
  7. Moderate to severe asthma or other obstructive lung disease requiring chronic use (> 2 days/week) of an inhaled β2-selective adrenergic agonist < 7 days of the Randomization Visit.
  8. Untreated thyroid disease, in the opinion of the Investigator, at the Randomization Visit.
  9. Serum potassium < 3.5 mmol/L at the Screening Visit.
  a. Lab value will be assessed by the central lab at the Screening Visit and any exclusionary results must be corrected prior to randomization as documented by either the central or local lab.
  10. Renal failure requiring dialysis, serum creatinine > 2.5 mg/dL, or an estimated creatinine clearance < 30 mL/min (Cockcroft-Gault) at the Screening Visit.
  a. Lab values will be assessed by the central lab at the Screening Visit and any exclusionary results must be corrected prior to randomization as documented by either the central or local lab.
  11. Significant intrinsic liver disease or a total bilirubin > 2.5 mg/dL at the Screening Visit.
  a. Lab value will be assessed by the central lab at the Screening Visit and any exclusionary results must be corrected prior to randomization as documented by either the central or local lab.
  12. Participation in a clinical study or treatment with an investigational drug or device within 30 days of the Screening Visit (or 5 half-lives of the investigational agent, whichever is longer).
  13. Comorbid condition or illness which, in the opinion of the Investigator, may limit life expectancy to less than 5 years.
  14. Serious or active medical or psychiatric condition which, in the opinion of the Investigator, may interfere with treatment, assessment, or compliance with the protocol.
  15. History of alcohol, drug, or chemical abuse that, in the opinion of the Investigator, could impair or limit the patient's full participation in the study.

Relevance to patient case: not relevant